102 related articles for article (PubMed ID: 16741917)
1. The DU145 human prostate carcinoma cell line harbors a temperature-sensitive allele of p53.
Bajgelman MC; Strauss BE
Prostate; 2006 Sep; 66(13):1455-62. PubMed ID: 16741917
[TBL] [Abstract][Full Text] [Related]
2. Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells.
Gurova KV; Rokhlin OW; Budanov AV; Burdelya LG; Chumakov PM; Cohen MB; Gudkov AV
Cancer Res; 2003 Jun; 63(11):2905-12. PubMed ID: 12782597
[TBL] [Abstract][Full Text] [Related]
3. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles.
Isaacs WB; Carter BS; Ewing CM
Cancer Res; 1991 Sep; 51(17):4716-20. PubMed ID: 1873816
[TBL] [Abstract][Full Text] [Related]
4. PC3, but not DU145, human prostate cancer cells retain the coregulators required for tumor suppressor ability of androgen receptor.
Litvinov IV; Antony L; Dalrymple SL; Becker R; Cheng L; Isaacs JT
Prostate; 2006 Sep; 66(12):1329-38. PubMed ID: 16835890
[TBL] [Abstract][Full Text] [Related]
5. Stable expression of temperature-sensitive p53: a suitable model to study wild-type p53 function in pancreatic carcinoma cells.
Nuevemann D; Christgen M; Ungefroren H; Kalthoff H
Oncol Rep; 2006 Sep; 16(3):575-9. PubMed ID: 16865258
[TBL] [Abstract][Full Text] [Related]
6. Distinct effects of annexin A7 and p53 on arachidonate lipoxygenation in prostate cancer cells involve 5-lipoxygenase transcription.
Torosyan Y; Dobi A; Naga S; Mezhevaya K; Glasman M; Norris C; Jiang G; Mueller G; Pollard H; Srivastava M
Cancer Res; 2006 Oct; 66(19):9609-16. PubMed ID: 17018618
[TBL] [Abstract][Full Text] [Related]
7. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells.
Fujita Y; Kojima K; Hamada N; Ohhashi R; Akao Y; Nozawa Y; Deguchi T; Ito M
Biochem Biophys Res Commun; 2008 Dec; 377(1):114-9. PubMed ID: 18834855
[TBL] [Abstract][Full Text] [Related]
8. Analysis of p53 status in human cell lines using a functional assay in yeast: detection of new non-sense p53 mutation in codon 124.
Smardová J; Pavlová S; Svitáková M; Grochová D; Ravcuková B
Oncol Rep; 2005 Oct; 14(4):901-7. PubMed ID: 16142349
[TBL] [Abstract][Full Text] [Related]
9. p53 controls hPar1 function and expression.
Salah Z; Haupt S; Maoz M; Baraz L; Rotter V; Peretz T; Haupt Y; Bar-Shavit R
Oncogene; 2008 Nov; 27(54):6866-74. PubMed ID: 18820708
[TBL] [Abstract][Full Text] [Related]
10. Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity.
Brazda V; Muller P; Brozkova K; Vojtesek B
Biochem Biophys Res Commun; 2006 Dec; 351(2):499-506. PubMed ID: 17070499
[TBL] [Abstract][Full Text] [Related]
11. Loss of p53 expression correlates with metastatic phenotype and transcriptional profile in a new mouse model of head and neck cancer.
Ku TK; Nguyen DC; Karaman M; Gill P; Hacia JG; Crowe DL
Mol Cancer Res; 2007 Apr; 5(4):351-62. PubMed ID: 17426250
[TBL] [Abstract][Full Text] [Related]
12. Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer.
Liu X; Elojeimy S; El-Zawahry AM; Holman DH; Bielawska A; Bielawski J; Rubinchik S; Guo GW; Dong JY; Keane T; Hannun YA; Tavassoli M; Norris JS
Mol Ther; 2006 Nov; 14(5):637-46. PubMed ID: 16887394
[TBL] [Abstract][Full Text] [Related]
13. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway.
Zhang AL; Russell PJ; Knittel T; Milross C
Prostate; 2007 Nov; 67(15):1630-40. PubMed ID: 17823933
[TBL] [Abstract][Full Text] [Related]
15. The autocrine human secreted PDZ domain-containing protein 2 (sPDZD2) induces senescence or quiescence of prostate, breast and liver cancer cells via transcriptional activation of p53.
Tam CW; Liu VW; Leung WY; Yao KM; Shiu SY
Cancer Lett; 2008 Nov; 271(1):64-80. PubMed ID: 18639375
[TBL] [Abstract][Full Text] [Related]
16. DNA binding and selective gene induction by different forms of the p53 protein.
Mayelzadeh F; Martinez JD
Oncogene; 2007 May; 26(21):2955-63. PubMed ID: 17130840
[TBL] [Abstract][Full Text] [Related]
17. Reversible dysfunction of wild-type p53 following homeodomain-interacting protein kinase-2 knockdown.
Puca R; Nardinocchi L; Gal H; Rechavi G; Amariglio N; Domany E; Notterman DA; Scarsella M; Leonetti C; Sacchi A; Blandino G; Givol D; D'Orazi G
Cancer Res; 2008 May; 68(10):3707-14. PubMed ID: 18483253
[TBL] [Abstract][Full Text] [Related]
18. p53 controls prostate-derived factor/macrophage inhibitory cytokine/NSAID-activated gene expression in response to cell density, DNA damage and hypoxia through diverse mechanisms.
Kelly JA; Lucia MS; Lambert JR
Cancer Lett; 2009 May; 277(1):38-47. PubMed ID: 19100681
[TBL] [Abstract][Full Text] [Related]
19. Transcription regulation by mutant p53.
Weisz L; Oren M; Rotter V
Oncogene; 2007 Apr; 26(15):2202-11. PubMed ID: 17401429
[TBL] [Abstract][Full Text] [Related]
20. [DNA damage induces BRCA1 distribution alteration in prostate cancer cell lines].
Wang CY; Sun SK; Fu WJ; Song T; Cai W; Gao JP; Hong BF; Wang XX; Wang H
Zhonghua Nan Ke Xue; 2008 Aug; 14(8):685-9. PubMed ID: 18817338
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
